Search Results
Aug 31, 2026, 08:22 ET CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
with no new safety signals identified.Proof of CTLA-4 activities and efficacyDose-dependent upregulation of ICOS on CD4+ T cells was observed as a pharmacodynamic biomarker of CTLA-4 blockade. Activity was also seen in "cold tumor" not sensitive to PD-(L)1 mAb:
More news about: CStone Pharmaceuticals
Aug 31, 2026, 08:00 ET Veloxis Pharmaceuticals Doses First Patient in RENGEVITY-201 Phase 2 Trial of Pegrizeprument for the Prevention of Organ Rejection in Kidney Transplant Recipients
and blocks CD28‑mediated effector-T cell costimulation, without blocking CTLA-4, an important protein found on T cells that naturally helps keep the body's immune responses in check. Pegrizeprument is, therefore, expected to have a dual mechanism of action where in a direct manner, it blocks CD28‑mediated
More news about: Veloxis Pharmaceuticals
Aug 31, 2026, 07:30 ET Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd).SELECT IMPORTANT SAFETY INFORMATIONWarnings and PrecautionsThrombocytopenia:
More news about: Karyopharm Therapeutics Inc.
Aug 31, 2026, 05:35 ET Nevada Organic Phosphate Announces Continued Excellent Low Heavy Metal Assays for Drill Hole MM26-10 at Murdock Mountain and Promotional Activity Engagement
AsCdCo
More news about: Nevada Organic Phosphate Inc.
Aug 28, 2026, 19:00 ET 디지털 미러 선도기업 와이포어, 북미에서 지능형 미러 전체 라인업 공개
검증된 양산 역량을 확보했으며, 이를 바탕으로 북미 시장에 진출했다. 이번 라인업에는 와이포어의 독자적인 액정(LC) 기술이 적용되어 기존 EC 솔루션보다 뛰어난 광학 선명도와 눈부심 방지 반응 성능을 제공한다.이 플랫폼은 25ms 이하의 초저지연과 2,250cd/m²를 초과하는 휘도로 최대 8MP 입력을 지원한다. 여기에 독자적인 ISP 튜닝 기술을 결합해 저조도, 눈부심, 악천후 상황에서도 선명한 시야를 보장하며, 500g 미만 무게의 5mm 초슬림 베젤 패키징으로 구현됐다.현지화 기반으로 북미 모빌리티
More news about: YFORE
Aug 28, 2026, 15:39 ET デジタルミラーのパイオニアであるYFORE、北米でスマートミラーのフルラインナップを発表
ションに比べ、優れた光学的な透明度と防眩性能を発揮します。このプラットフォームは、最大8MPの入力に対応し、25ms以下の超低遅延と、2,250 cd/m²を超える輝度を実現しています。独自のISPチューニングと相まって、薄暗い、眩しい、あるいは過酷な天候下でも鮮明な視界を確保します。これらは、厚さ5mmの超薄型ベゼルに収められ、重量は500g未満となっています。地域に根ざし、北米のモビリティを活性化YFORE U.S.は、現地での研究開発、製造、カ
More news about: YFORE
Aug 28, 2026, 14:42 ET YFORE, pionnier des rétroviseurs numériques, dévoile sa gamme complète de rétroviseurs intelligents en Amérique du Nord
La plateforme prend en charge des entrées allant jusqu'à 8 MP, avec une latence ultra-faible ≤ 25 ms et une luminosité supérieure à 2 250 cd/m². Associé à un réglage ISP exclusif, il garantit une vision nette en conditions de faible luminosité, en cas d'éblouissement et par mauvais temps, le
More news about: YFORE
Aug 28, 2026, 10:42 ET YFORE, pionera en espejos digitales, presenta su gama completa de espejos inteligentes en Norteamérica
EC tradicionales.La plataforma admite entradas de hasta 8 MP con una latencia ultrabaja de ≤25 ms y un brillo superior a 2.250 cd/m². En combinación con el ajuste del ISP patentado, garantiza una visión nítida en condiciones de poca luz, deslumbramiento y condiciones meteorológicas
More news about: YFORE
Aug 28, 2026, 09:59 ET YFORE, Pionier im Bereich digitaler Spiegel, stellt in Nordamerika sein komplettes Sortiment an intelligenten Spiegeln vor
Die Plattform unterstützt Eingänge mit bis zu 8 MP bei einer extrem niedrigen Latenz von ≤ 25 ms und einer Helligkeit von über 2.250 cd/m². In Kombination mit einer proprietären ISP-Optimierung gewährleistet sie eine scharfe Sicht bei schlechten Lichtverhältnissen, Blendung und widrigen
More news about: YFORE
Aug 28, 2026, 07:00 ET CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene
by CRT-402, its CD19-directed, transient and repeat-dose in vivo CAR-T program, currently in a first-in-human Phase 1/2 clinical study (NCT07778446). CRT-402 establishes the foundation of CREATE's CD19 development strategy, which the company is expanding through dual-target CD19 × BCMA immune
More news about: CREATE Medicines, Inc.
Aug 28, 2026, 06:47 ET Digital Mirror Pioneer YFORE Unveils Full Intelligent Mirror Lineup in North America
traditional EC solutions.The platform supports up to 8MP inputs with an ultra-low latency of ≤25ms and brightness exceeding 2,250 cd/m². Paired with proprietary ISP tuning, it ensures crisp vision in low light, glare, and harsh weather—packaged within a 5mm ultra-slim bezel weighing
More news about: YFORE
Aug 28, 2026, 06:23 ET Digital Mirror Pioneer YFORE Unveils Full Intelligent Mirror Lineup in North America
traditional EC solutions.The platform supports up to 8MP inputs with an ultra-low latency of ≤25ms and brightness exceeding 2,250 cd/m². Paired with proprietary ISP tuning, it ensures crisp vision in low light, glare, and harsh weather—packaged within a 5mm ultra-slim bezel weighing
More news about: YFORE
Aug 27, 2026, 22:44 ET Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
in lung cancer, as well as first-line MSS/pMMR colorectal cancer, first-line PD-L1-positive head and neck squamous cell carcinoma (in combination with CD47 antibody versus pembrolizumab), first-line biliary tract cancer (versus a durvalumab-based regimen), first-line triple-negative breast cancer, first-line
More news about: Akeso, Inc.
Aug 27, 2026, 16:01 ET Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
abolishment of CTC clusters and significant reduction in terminally exhausted CD8+ T cells, alongside overall improvement in markers of immune function.Translational analyses demonstrated reductions in terminally exhausted CD8+ T cells across all six patients, with a median reduction of 51 percent
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 10:29 ET /C O R R E C T I O N -- Yamaha/
dramatically improve the TV listening experience without added complexity. Additional analog and digital inputs also accommodate components such as a CD player, a turntable (with compatible phono preamplifier) or other audio devices.Optimized for Every Listening SpaceIncluded with
More news about: Yamaha
Aug 27, 2026, 10:15 ET CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
with no new safety signals identified.Proof of CTLA-4 activities and efficacyDose-dependent upregulation of ICOS on CD4+ T cells was observed as a pharmacodynamic biomarker of CTLA-4 blockade. Activity was also seen in "cold tumor" not sensitive to PD-(L)1 mAb:
More news about: CStone Pharmaceuticals
Aug 27, 2026, 10:04 ET Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
I trial in the United States. In July 2026, HBM2001 obtained NMPA IND clearance to commence a Phase I trial in China.HBM7020 is a BCMA×CD3 bispecific antibody generated using the HBICE® technology and Harbour Mice® platform. Following the global strategic collaboration
More news about: Harbour BioMed
Aug 27, 2026, 09:00 ET Sonar Launches SonarQube Hunter Agent to Catch Logic-based Security Flaws
context.Because it runs in the background, on a set schedule or on demand, SonarQube Hunter Agent never blocks a pull request or slows down CI/CD. Further, as every finding is confirmed before it surfaces, teams spend their time on real risk instead of sorting through noise.SonarQube Hunter
More news about: Sonar
Aug 27, 2026, 02:00 ET AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
SKYRIZI® (risankizumab) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely active Crohn's disease (CD). The application to the EMA is supported by the recently shared positive data from the
More news about: AbbVie
Aug 26, 2026, 06:00 ET The Crime Before the Crime
30-year-old security technology: a badge reader. That badge reader is completely unintelligent. Can you imagine listening to music on a boom box or CD? That's how old badge technology is. Firing security personnel is not the answer, because we haven't given security directors the technology to do their
More news about: Alcatraz
Aug 25, 2026, 17:00 ET Commodore Jacks Into Night City With the Commodore 77, an All-New Cyberpunk 2077 Collaboration
Hunt and its expansions. In collaboration with TRIGGER, CD PROJEKT RED also created the award-winning Netflix anime series Cyberpunk: Edgerunners, set in the same universe as the game. CD PROJEKT RED is part of the CD PROJEKT RED Capital Group. CD PROJEKT RED S.A. is listed on the Warsaw Stock Exchange
More news about: Commodore International Corporation
Aug 25, 2026, 08:44 ET Fosun Pharma Announces 2026 Interim Results
associated with neurofibromatosis type 1 (NF1) has been accepted and granted priority review by the NMPA.- The NDA for Velinotamig (GR1803), a BCMA × CD3 bispecific antibody for multiple myeloma, has been accepted.Lead pipeline candidates HLX43 and HLX22 are progressing in international multi-center
More news about: Fosun Pharma
Aug 25, 2026, 08:06 ET Cellenkos Receives FDA Fast Track Designation for CK0803 in Amyotrophic Lateral Sclerosis (ALS)
Tregs have been shown to rely on LFA-1 (CD11a/CD18) rather than α4-integrin (VLA-4) to migrate into the CNS, and LFA-1-deficient mice exhibit more severe disease and reduced CNS Treg frequency — a mechanism the company believes is directly relevant to CK0803's CD11a-high design and potentially complementary
More news about: Cellenkos, Inc.
Aug 25, 2026, 06:15 ET Innovent Announces 2026 Interim Results and Business Updates
strategy, the Company is advancing next-generation assets including IBI363 (PD-1/IL-2α-biased), IBI343 (CLDN18.2 ADC), and IBI3003 (GPRC5D/BCMA/CD3) into late-stage clinical development, establishing long-term growth drivers and competitive advantages across multiple strategic areas.Meanwhile,
More news about: Innovent Biologics
Aug 25, 2026, 06:00 ET 58% of Americans Can't Name the Security Failure Behind Intruder Breaches at Harvard, UCLA and 30 Rockefeller Center
30-year-old security technology: a badge reader. That badge reader is completely unintelligent. Can you imagine listening to music on a boom box or CD? That's how old badge technology is. Firing security personnel is not the answer, because we haven't given security directors the technology to do their
More news about: Alcatraz